Skip to content

How long drug registration review takes in China

Oak
Two glass tubes of different lengths each carry an amber capsule across a laboratory bench toward a sealed steel chamber.

The Drug Registration Measures set a review period of 200 working days for a marketing application and 60 for a clinical trial application.1 The administrative decision follows within 20 working days, and the certificate within 10 more.1 Since September 2025 a qualifying clinical trial application for an innovative drug is reviewed within 30 working days.2

Each period is the longest time allowed for one step. Article 125 counts the periods in working days, and Article 103 leaves four kinds of time out of them.1

The periods step by step

StepPeriod in working days
Formal check, with a decision to accept, require correction or refuse5
Review and approval of a clinical trial application60
Review of a marketing application200
Review of a marketing application under priority review130
Priority review of a rare disease drug in urgent clinical need and marketed abroad70
Review of a stand-alone application for a generic chemical active ingredient200
Approval of the generic name30
Suitability review of a non-prescription drug30
Re-registration120
Administrative decision20
Issue and delivery of the certificate10

A supplementary application during a clinical trial has the same 60 working days as the trial application.1 The review of a related application, such as an ingredient reviewed with a preparation, takes the period of the preparation.1

Supplementary applications after marketing

Article 96 sets three periods for a supplementary application that requires approval.1

Supplementary applicationPeriod in working days
A single change60
Several changes filed together80
A change involving review of trial data, or inspection and testing200

Clinical trials

The Drug Administration Law fixes the period for a clinical trial application in statute. The regulator decides within 60 working days of acceptance and notifies the sponsor. Where no notice is given in that time, consent is deemed given.3

No new technical materials may be added while a clinical trial application is under review. Where new research is needed, the applicant may withdraw and apply again.1

The 30-working-day channel

The National Medical Products Administration issued Announcement No. 86 of 2025 on 9 September 2025, in force from publication. A qualifying clinical trial application for an innovative drug is reviewed and approved within 30 working days of acceptance.2

The application must be for a trial of a Class 1 innovative drug, whether a traditional Chinese medicine, a chemical drug or a biological product. It must also meet one of three conditions.2

  • It is a key innovative drug of clear clinical value that is supported under the national policy of support for innovative drugs.
  • It is an innovative paediatric drug, rare disease drug or traditional Chinese medicine published as qualifying by the Center for Drug Evaluation.
  • It is developed globally at the same time.

The third condition covers Phase I and Phase II trials of such a product. It also covers a Phase III international multicentre trial that a principal investigator at a Chinese institution leads or jointly leads.2

The applicant undertakes to start the trial within 12 weeks of approval.2 The Center decides on acceptance within 5 working days. Where a difficult question requires a technical consultation or an expert meeting, the Center tells the applicant within 20 working days of acceptance. The period of 60 working days then applies.2

Inspection and testing

Inspection and testing run inside the review period and have their own periods.1

StepPeriod in working days
Notice from the Center for Drug Evaluation to start inspectionWithin 40 after acceptance
Completion of on-site production inspectionIn principle 40 before the review period ends
Sample testing60
Sample testing with verification of the standard90
Supplementing materials during testing30
Testing report to the Center for Drug EvaluationIn principle 40 before the review period ends

What extends the period

The Center for Drug Evaluation in principle asks for supplementary technical materials once. It lists every question and gives the applicant 80 working days to respond.1 That time is left out of the review period. When the Center has received all of the materials, the review starts again. The review period is then extended by one third, or by one quarter under priority review.1

Where only an explanation of the filed materials is needed, the applicant has 5 working days to provide it.1

A technical body may also extend a period for special circumstances, by up to one half of the original period.1

Time that is left out

Article 103 lists the time that does not count toward a period.1

  • time the applicant takes to supplement materials, to rectify after inspection, and to check the production process, quality standard and package insert as required
  • delay of inspection, testing or an expert meeting caused by the applicant
  • time during which review and approval are suspended under laws and regulations
  • time taken by an inspection abroad, where one is started

Pilots under Document 53

An opinion of the General Office of the State Council, dated 30 December 2024, provides for two pilots. A provincial regulator applies and the national regulator agrees.4

PilotPeriod nowPeriod in the pilot
Review and approval of clinical trials of innovative drugs60 working days30 working days
Review of supplementary applications that need inspection and testing200 working days60 working days

Questions people also ask

How long is the review of a new drug application in China?

The review period is 200 working days, 130 under priority review, and 70 for a rare disease drug in urgent clinical need that is marketed abroad.1

Is the decision included in the 200 working days?

The administrative decision has its own period of 20 working days, and the certificate is issued within 10 working days after it.1

What happens when the reviewer asks for more data?

The applicant has 80 working days to respond, and that time is left out of the period. The review period is then extended by one third, or by one quarter under priority review.1

Which trials qualify for the 30-working-day channel?

The channel is for clinical trials of Class 1 innovative drugs that meet one of three conditions. The applicant undertakes to start the trial within 12 weeks of approval.2

Does an inspection abroad count toward the period?

Where an inspection abroad is started, the time it takes is left out of the period.1

Footnotes

  1. Measures for the Administration of Drug Registration (State Administration for Market Regulation Order No. 27), Articles 87, 88, 94 to 103 and 125. https://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5498012.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17

  2. National Medical Products Administration, Announcement on Optimising the Review and Approval of Clinical Trials of Innovative Drugs, No. 86 of 2025. https://yjj.sh.gov.cn/qtgzwj/20250912/c840a6ddf1cf4c58a4855427d0f9f476.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  3. Drug Administration Law of the People’s Republic of China (revised 2019), Article 19. http://www.gd.gov.cn/zwgk/wjk/zcfgk/content/post_2521598.html ↩

  4. General Office of the State Council, Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation and Promoting the High-Quality Development of the Pharmaceutical Industry, Guo Ban Fa [2024] No. 53, items 8 and 9. https://www.gov.cn/zhengce/content/202501/content_6996115.htm ↩

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.